- Dr. Reddy's Laboratories has reached an agreement with the Russian authorities to conduct clinical trials and distribution of the COVID-19 Sputnik V vaccine in India.
- The pharmaceutical company is mostly a generics play but also spends a large amount of revenues on R&D.
- There has been double-digit growth despite some price and volume led sales challenges in certain geographies.
- Financial position is strong with the recent acquisition constituting a potential for more growth.
- Given the pipeline, existing and potential growth level as well as financial position, Dr. Reddy's Laboratories is a buy with a 20% potential upside depending on clinical results but do expect some volatility along the way.
For further details see:
Dr. Reddy's Laboratories: A High Growth Generics Plus COVID-19 Play